Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
about
Erythropoietin: new directions for the nervous systemMouse models of polyglutamine diseases: review and data table. Part IMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?Neurodegenerative disease and adult neurogenesisProgressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease.Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads databaseErythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.A mitochondrial basis for Huntington's disease: therapeutic prospects.Adult neurogenesis in neurodegenerative diseases.The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration.Erythropoietin: a multimodal neuroprotective agent.Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration.Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment.Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.The Benefits of Exercise on Structural and Functional Plasticity in the Rodent Hippocampus of Different Disease Models.Erythropoietin does not preserve motor neurons in a mouse model of familial ALSEarly postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibitionAntidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
P2860
Q26828425-8FD9B938-59AD-461A-8BE2-1B3AFE73E10EQ26853025-C884B7FA-2C08-410E-A4EB-4356DCF39D77Q27005950-7518C1D0-FA53-4B47-9DCB-1212F7B5A5CDQ27012489-BB494991-9EF7-478B-8275-B1B4391AA11FQ28307113-07E0A171-3418-4317-8C9E-53ED30A6BEA1Q33239883-8988A740-1C31-48D7-A6B7-54F10D749986Q33326475-E7AE5B1A-1E4A-4641-83EE-B640806AD7A0Q33690991-9C494DA7-D147-474E-9E06-38E1D02FB3D9Q34319766-94FC133D-0CD7-47F9-9D92-741B5AE123CAQ35997721-A476F50C-9F58-42C6-91AE-E57F290B10C3Q36358871-612768A2-F5F1-4C75-8C95-00A203D6D9B9Q37358669-886141EF-1847-4B00-A520-BF8939F15339Q38174451-9196F22E-AE6B-44B0-B580-B57FE2FE34A9Q38400868-E8E3461B-72A2-4441-93AC-D69DC8F72BC9Q42055923-704C1EE5-8EB3-45C1-B3C4-E7346F0A1A4EQ42132275-2DCF9DB7-3916-460E-A53E-71C3FCED5ED1Q42729265-1E813B0E-60EE-4A83-8E7D-DF1FFE1BC43FQ42922791-86D20A89-B85D-4EC8-AEF9-B7F52B852BA3Q45290768-FAE0146A-B6EC-4D72-BA49-0FB7142A0D8FQ45300776-67C53C15-6881-4EE3-A859-72B89D56F1E9Q45305684-6C6751FB-FA08-4197-866C-C1CA6A5BD766Q54945662-35CB6A6E-4B0C-4333-B347-86C2C26DBF71Q58127127-679462E3-77FD-49EA-8B1E-5EFDBDC956C9Q58700269-9D656F69-38E0-47AC-A34F-7F52AF8CBD74Q58780496-A1E37685-B5FD-4FA2-9B28-95DDAD480314
P2860
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@ast
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@en
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@nl
type
label
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@ast
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@en
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@nl
prefLabel
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@ast
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@en
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@nl
P2093
P2860
P356
P1433
P1476
Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice
@en
P2093
Asa Petersén
Joana M A C Gil
Marcel Leist
Natalija Popovic
P2860
P2888
P356
10.1186/1471-2202-5-17
P407
P577
2004-05-10T00:00:00Z
P5875
P6179
1028090856